Arkolith/Insider Trading/OKUR/Form 4

Saccomano Nicholas A

President and CEO, DirectorOnKure Therapeutics, Inc. (OKUR) · full profile →Form 4 · filed Oct 8, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
1 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 4, 2024Grant(A)5K——5K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 4, 2024Grant(A)1K——1K
Oct 4, 2024Grant(A)542K—$0542K
Oct 4, 2024Grant(A)8K——8K
Oct 4, 2024Grant(A)17K——17K
Oct 4, 2024Grant(A)2K——2K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-024921) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML